



TO BME GROWTH

Barcelona, May 9, 2024

[Translation from the [original document](#) published on May 7, 2024]

Pursuant to article 17 of Regulation (EU) 596/2014 of the European Parliament and of the Council of 16 April, on market abuse, and article 228 of the consolidated text of the Law on Market Securities and Investment Services, approved by Royal Legislative Decree 6/2023 of 17 March and its concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity, Holaluz-Clidom, S.A. ("Holaluz" or the "Company") hereby discloses the following

INSIDER INFORMATION

The Company continues to progress in refinancing its activity and currently has two alternatives open. Both are pending confirmation from the ICF to be formalized.

1. Alternative reported on April 2nd: ICF loan for €10 million, Avançsa loan for €3 million, convertible loans from two family offices for €1.8 million, and an Equity Line for up to €7 million.
2. New additional alternative: ICF loan for €10 million, Avançsa loan for €3 million, and convertible loans for €7 million with an investor/industrialist from the sector.

Once one of the two alternatives is confirmed, the company will provide timely information to the market. Additionally, the company has already formalized a financing operation for an amount of €4 million, which has already been disbursed.

In compliance with the provisions of the BME MTF Equity Circular 3/2020, it is expressly stated that the information provided has been prepared under the exclusive responsibility of the Company and its directors.

Carlota Pi Amorós

coFounder and President
HOLALUZ-CLIDOM, S.A